How to Buy Dexcom Stock
Dexcom Inc
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems.
Dexcom stock last closed at $79.93, up 1.67% from the previous day, and has increased 17.23% in one year. It has overperformed other stocks in the Medical Devices industry by 1.08 percentage points. Dexcom stock is currently +47.72% from its 52-week low of $54.11, and -13.67% from its 52-week high of $92.59.
At the moment, there are 377.36M DXCM shares outstanding. The market capitalization of DXCM is $30.16B. In the past 24 hours, 5.91M DXCM shares were traded.
How to Buy Dexcom Stock
Wondering how to invest in Dexcom stock? Here's how.
- Choose where to buy Dexcom stock: You need to choose a stock brokerage, but don't worry - we've tried dozens of online brokerages and apps to help you figure out where to buy Dexcom stock.
- Create a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your brokerage account: Choose your payment method and add your info.
- Research Dexcom stock: The Dexcom ticker symbol is DXCM. Is Dexcom stock a good investment? Should you buy shares of DXCM? How do DXCM's underlying business fundamentals look? Do top analysts think Dexcom is a good buy? Why has DXCM's stock price moved recently? (Hint: Our stock market analysis tools can help you decide if DXCM is a good stock to buy).
- Execute your DXCM purchase: Decide if you will purchase DXCM shares at the current market price or use a limit order to buy DXCM shares at a particular price.
- Keep an eye on your DXCM position: Create a watchlist to monitor your investment in Dexcom stock.
Step 1: Choose where to buy Dexcom stock
You will need an online brokerage account to access the NASDAQ market and buy DXCM stock.
Our preferred brokerage: eToro
We believe that eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of shares by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've selected your brokerage, it's time to fill out some personal information so you are able to invest in DXCM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to open your new trading account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you have created your account on stock apps to use, your next step is to transfer the money for your investment:
Check out the video below to see the process of transferring funds into your new brokerage account.
Step 4: Research Dexcom stock
Once you have selected the best place to buy Dexcom stock, it's crucial to evaluate their stock prior to buying, so you truly wrap your head around the risk as well as the upside.
Dexcom quick stats
Dexcom Due Diligence Checks
WallStreetZen was designed to help everyday investors do more accurate fundamental analysis in less time.
You can see all of the due diligence checks on DXCM's stock page.
Is DXCM stock overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge DXCM's intrinsic value.
Using relative valuations metrics:
- DXCM could be overvalued based on its P/E ratio of 30.86x, relative to Medical Devices industry P/E ratio of 22.03x
- DXCM may be overvalued based on its P/B ratio of 11.51x, relative to Medical Devices industry P/B ratio of 3.22x
- DXCM may be overvalued based on its PEG ratio of 2.31x
You can do additional valuation analysis on DXCM's stock here.
DXCM Financial Health
Passed Financial Due Diligence Checks:
- DXCM profit margin has gone up from 13.3% to 20.1% in the past year.
- DXCM earnings of $1.30B is not enough to cover its interest payments.
- There are more short-term assets than short-term liabilities on the DXCM balance sheet.
- DXCM's operating cash flow of $1.75B allows it to safely service it's debt of $1.35B.
- There are more short-term assets than long-term liabilities on the DXCM balance sheet.
Failed Financial Due Diligence Checks:
- Total DXCM debt is higher than 5 years ago, relative to shareholder equity.
- DXCM has a relatively high debt to equity ratio of 1.46.
Is DXCM stock a Buy, Hold, or Sell, according to analysts?
Out of 19 Wall Street analysts who give recommendations on DXCM, the consensus analyst rating on Dexcom is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they investment advice.
Latest DXCM Analyst Upgrades/Downgrades
Steve Silver, a top 41% analyst from Argus Research maintains DXCM with a strong buy rating and raises their DXCM price target from $86.00 to $96.00, on Aug 4, 2026.
William Plovanic, a top 13% analyst from Canaccord Genuity maintains DXCM with a strong buy rating and raises their DXCM price target from $82.00 to $90.00, on Aug 3, 2026.
Canaccord Genuity's William Plovanic raised their price target on Dexcom (NASDAQ: DXCM) by 9.8% from $82 to $90 on 2026/08/04. The analyst maintained their Strong Buy rating on the stock.
DexCom reported its Q2 2026 earnings.
Raising their price target, Plovanic opined that although management upped its guidance for the second quarter running, it was only to account for the quarter's results.
Looking ahead, the analyst reminded readers that DexCom is closing in on CGM's coverage decision for T2 non-insulin patients, which should significantly reshape its revenue and EPS growth paths.
Earnings Report
For Q2 2026, Dexcom reported:
- EPS of $0.70, which beat the Zacks Consensus Estimate of $0.61 and, by 45.8%, Q2 2025’s $0.48.
- Revenue of $1.31B, which beat the Zacks Consensus Estimate by 1.01% and, by 13%, Q2 2025’s $1.16B.
For FY 2026, management guided:
- Revenue of $5.18B to $5.25B.
President & CEO Jake Leach commented: “During the quarter, we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long-term financial outlook through 2030.
“This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.”
Joanne Wuensch, a top 7% analyst from Citigroup maintains DXCM with a strong buy rating and raises their DXCM price target from $84.00 to $88.00, on Jul 31, 2026.
Anthony Petrone, a top 5% analyst from Mizuho maintains DXCM with a buy rating and raises their DXCM price target from $90.00 to $95.00, on Jul 31, 2026.
Robbie Marcus, a top 17% analyst from JP Morgan maintains DXCM with a hold rating and raises their DXCM price target from $65.00 to $82.00, on Jul 31, 2026.
You can dig deeper into what analysts are forecasting on the Dexcom stock forecast page.
DXCM Momentum
How is DXCM performing as a company?
Last year, DXCM earnings were $999.70M. During the past 5 year, DXCM's earnings have increased by 9.77% per year. This was slower than the Medical Devices industry average of 11.16%.
Last year, DXCM revenue was $4.97B. In the past 5 year, DXCM's revenue has grown by 18.02% per year. This was faster than the Medical Devices industry average of 8.62%.
You can analyze DXCM's earnings and revenue performance here.
What are DXCM executives and large shareholders up to?
Over the last year, executives and large shareholders at DXCM have sold more shares than they have bought.
Sadie Stern, CHRO;EVP of DXCM, was the latest DXCM insider to sell. They sold $201,660.30 worth of DXCM stock on Oct 27, 2026.
Research more about who owns DXCM shares here.
Does DXCM provide a stable income stream?
No, Dexcom doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your DXCM purchase
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at an exact dollar amount, place a limit order.
Hit the Open Trade button and eToro will execute your order.
If you want more info about investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your DXCM position
Now that you own some DXCM shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to get notified of important updates regarding your DXCM stock.
DXCM Feed
How to Buy Stock in Dexcom
To reiterate, here are the 6 steps for buying Dexcom stock:
- Choose where to buy Dexcom stock
- Create a brokerage account
- Put funds into your brokerage account
- Research Dexcom stock
- Execute your DXCM purchase
- Keep an eye on your DXCM position
If you need a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your investment in Dexcom, create a watchlist on WallStreetZen today.
Other "How To" Guides You Might Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.